Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Trial of Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer

NCT05425862 is registered in ClinicalTrials.gov with Peter MacCallum Cancer Centre, Australia as lead sponsor.

NCT NCT05425862
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05425862 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Trial of Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer
Lead sponsor
Peter MacCallum Cancer Centre, Australia
Phase
Phase 1
Overall status
Suspended
Start date
October 21, 2022
Completion date
December 30, 2025
Enrollment
48 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration resistant prostate cancer (mcrpc)